What is Lab Central?
Founded in 2013, LabCentral operates as a specialized non-profit launchpad designed to mitigate the high barriers to entry for early-stage biotech and life sciences start-ups. The company provides a comprehensive suite of services, including state-of-the-art laboratory facilities, administrative support, and a dedicated operations team. By centralizing these essential resources, LabCentral enables founders to focus exclusively on scientific discovery and commercialization. Its market position is unique, serving as a bridge between academic research and scalable enterprise-level operations, effectively de-risking the path for emerging innovators in the competitive Massachusetts life sciences corridor.
How much funding has Lab Central raised?
Lab Central has raised a total of $22.8M across 2 funding rounds:
Debt
$350K
Other Financing Round
$22.4M
Debt (2020): $350K with participation from PPP
Other Financing Round (2021): $22.4M led by Thermo Fisher Scientific and Waters
Key Investors in Lab Central
Thermo Fisher Scientific
A global leader in serving science, providing analytical instruments, laboratory equipment, and software solutions to the life sciences sector.
Waters
A specialty measurement company focused on chromatography, mass spectrometry, and thermal analysis innovations for laboratory environments.
PPP
Public-Private Partnership
What's next for Lab Central?
With the recent influx of capital, LabCentral is well-positioned to expand its operational footprint and enhance its service offerings for the next generation of biotech pioneers. The strategic alignment with major industry partners suggests a focus on deepening the integration between laboratory infrastructure and advanced analytical capabilities. As the organization moves forward, it will likely prioritize the scaling of its facility management models and the expansion of its programming to support a broader range of therapeutic and diagnostic technologies. This growth phase is expected to further cement LabCentral's influence in the global life sciences landscape, ensuring that the pipeline of innovation remains robust and well-supported by institutional-grade resources.
See full Lab Central company page
